Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy.
Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy.
Valentina
V
Damato
Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy.
Amelia
A
Evoli
Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy2Don Gnocchi ONLUS Foundation, Milan, Italy.
Raffaele
R
Iorio
D006801:Humans; D007155:Immunologic Factors; D009471:Neuromyelitis Optica; D000069283:Rituximab
D007155:Immunologic Factors; D000069283:Rituximab